| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/J.GASTRO.2009.09.067 |
| P698 | PubMed publication ID | 19861128 |
| P50 | author | Thierry Poynard | Q43252014 |
| P2093 | author name string | Hashem El-Serag | |
| Gary L Davis | |||
| Miriam J Alter | |||
| Linda W Jennings | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 513-21, 521.e1-6 | |
| P577 | publication date | 2009-10-25 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression | |
| P478 | volume | 138 |
| Q40536482 | "Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research? |
| Q35174428 | "Seek, test, treat and retain" for hepatitis C in the United States criminal justice system. |
| Q36029791 | A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. |
| Q90160343 | A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy |
| Q35928666 | A bioinformatic and mechanistic study elicits the antifibrotic effect of ursolic acid through the attenuation of oxidative stress with the involvement of ERK, PI3K/Akt, and p38 MAPK signaling pathways in human hepatic stellate cells and rat liver |
| Q53572231 | A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. |
| Q34341819 | A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. |
| Q45174119 | A great time to invest in baby Boomer's hepatitis C! |
| Q42988684 | A nationwide seroepidemiology of hepatitis C virus infection in South Korea |
| Q37992195 | A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. |
| Q35131882 | A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. |
| Q45368430 | A siege of hepatitis: fighting a defiant virus |
| Q52306466 | A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act. |
| Q33861119 | ABO blood type correlates with survival in hepatocellular carcinoma following hepatectomy |
| Q38387667 | ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus |
| Q88475579 | Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study |
| Q38314738 | Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease? |
| Q58697778 | Advanced Hepatocellular Carcinoma Tumor Stage at Diagnosis in the 1945-1965 Birth Cohort Reflects Poor Use of Hepatocellular Carcinoma Screening |
| Q38161848 | After the cure: management of HCV after achievement of SVR. |
| Q34067956 | Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection |
| Q92801259 | Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease |
| Q57955412 | All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus |
| Q89910711 | An Interaction Between Glecaprevir, Pibrentasvir, and Colchicine Causing Rhabdomyolysis in a Patient With Chronic Renal Disease |
| Q38962270 | An effectiveness study of group psychoeducation for hepatitis C patients in community clinics |
| Q38371669 | An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma. |
| Q30453975 | An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver |
| Q42282187 | Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies |
| Q38079528 | Anemia management in patients with chronic viral hepatitis C. |
| Q37980899 | Anti-fibrotic therapy: lost in translation? |
| Q37130025 | Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection |
| Q50558502 | Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis. |
| Q37962184 | Are patients with Child's A cirrhosis and hepatocellular carcinoma appropriate candidates for liver transplantation? |
| Q35634124 | Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment |
| Q43447385 | Associations of chronic hepatitis C with metabolic and cardiac outcomes |
| Q38547705 | Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions |
| Q36155564 | Base pairing between hepatitis C virus RNA and microRNA 122 3' of its seed sequence is essential for genome stabilization and production of infectious virus. |
| Q34725990 | Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. |
| Q43042517 | Boceprevir |
| Q34690368 | Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study |
| Q42145002 | Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection |
| Q36702302 | Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C |
| Q36811958 | Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection |
| Q45344040 | Building bridges and providing transparency to the hepatitis C virus drug approval process. |
| Q38218611 | Building the multidisciplinary team for management of patients with hepatocellular carcinoma |
| Q57478112 | Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018 |
| Q36690763 | Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis |
| Q36292220 | Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study |
| Q44835949 | Burden of liver disease in Brazil |
| Q64892384 | Características demográficas actuales del virus de la hepatitis C. |
| Q41703119 | Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade |
| Q84498971 | Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population |
| Q59356897 | Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016 |
| Q27011203 | Changing the face of hepatitis C management - the design and development of sofosbuvir |
| Q38155505 | Chemoembolization in patients with hepatocellular carcinoma |
| Q87117255 | Chemoembolization of hepatocellular carcinoma |
| Q36418455 | Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? |
| Q40588090 | Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination |
| Q37148328 | Chronic hepatitis C virus (HCV) disease burden and cost in the United States |
| Q40057348 | Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. |
| Q26775011 | Chronic hepatitis C: This and the new era of treatment |
| Q47108259 | Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. |
| Q46222665 | Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C. |
| Q92373959 | Community screening for hepatitis C virus infection in a low-prevalence population |
| Q35089934 | Community-based HCV screening: knowledge and attitudes in a high risk urban population |
| Q42154570 | Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C. |
| Q56918825 | Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy |
| Q37620211 | Consequences of perceived stigma among patients with cirrhosis |
| Q88288702 | Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate |
| Q36421047 | Consilience in sarcopenia of cirrhosis |
| Q38906439 | Constitutional and functional genetics of human alcohol-related hepatocellular carcinoma. |
| Q92634905 | Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany |
| Q39749160 | Cost-Effectiveness of the Hepatitis C Self-Management Program |
| Q39478177 | Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal |
| Q39153261 | Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection |
| Q40584662 | Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients |
| Q36115516 | Cost-effectiveness and population outcomes of general population screening for hepatitis C. |
| Q35058571 | Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence |
| Q28540562 | Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C |
| Q37286544 | Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States |
| Q50552857 | Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. |
| Q39102936 | Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States |
| Q36479439 | Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. |
| Q35736293 | Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. |
| Q34310417 | Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response |
| Q40146969 | Could Adherence to Quality of Care Indicators for Hospitalized Patients With Cirrhosis-Related Ascites Improve Clinical Outcomes? |
| Q91656273 | Criteria for liver transplantation in hepatocellular carcinoma |
| Q38295834 | Cure of HCV related liver disease |
| Q34737843 | Current and future disease progression of the chronic HCV population in the United States |
| Q30473375 | Current status of novel antifibrotic therapies in patients with chronic liver disease |
| Q40528177 | Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis |
| Q36051195 | Declining liver graft quality threatens the future of liver transplantation in the United States |
| Q64922831 | Demographics of hepatitis C virus today. |
| Q42983413 | Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit |
| Q26822903 | Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis |
| Q38134312 | Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument |
| Q39537347 | Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis. |
| Q37962197 | Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences |
| Q38408866 | Diagnosis and treatment of hepatocellular carcinoma: An update |
| Q34461237 | Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIα in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma |
| Q37663921 | Direct-acting antiviral agents in patients with hepatitis C cirrhosis |
| Q38548066 | Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. |
| Q41201956 | Direct-acting antiviral treatment of chronic hepatitis C infection |
| Q40333753 | Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients |
| Q40428996 | Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis. |
| Q43042207 | Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus |
| Q43036082 | Donation after cardiac death organs for patients with hepatitis C virus: are we rolling the dice, or are they just as good as any? |
| Q30241648 | Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue? |
| Q37945270 | Drugs in development for chronic hepatitis C: a promising future |
| Q38609090 | Dry blood spot testing for hepatitis C in people who injected drugs: reaching the populations other tests cannot reach |
| Q38630475 | Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. |
| Q38714156 | Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection |
| Q37788253 | Early Interferon-Based Treatment After Detection of Persistent Hepatitis C Virus Infection: A Critical Decision |
| Q52560845 | Economic Impact and Complications of Treated and Untreated Hepatitis C Virus Patients in Turkey. |
| Q37027342 | Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients |
| Q34253963 | Economic burden of hepatitis C-associated diseases in the United States. |
| Q64068380 | Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals |
| Q43047944 | Economic model of a birth cohort screening program for hepatitis C virus |
| Q37604532 | Editorial commentary: Hepatitis C virus testing and drug use in north america; is there more than meets the eye? |
| Q59356607 | Effect of Hepatocellular Carcinoma on Mortality Among Individuals With Hepatitis B or Hepatitis C Infection in New York City, 2001-2012 |
| Q39315202 | Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. |
| Q40304878 | Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. |
| Q34451707 | Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre |
| Q64238219 | Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study |
| Q42269830 | Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients |
| Q93190724 | Electronic Consultations to Hepatologists Reduce Wait Time for Visits, Improve Communication, and Result in Cost Savings |
| Q37772514 | Emerging therapies for hepatitis C virus |
| Q27003319 | Emerging therapies for the treatment of hepatitis C |
| Q33862919 | Ending hepatitis C in the United States: the role of screening. |
| Q28085718 | Enhancing our understanding of current therapies for hepatitis C virus (HCV) |
| Q38118578 | Epidemiology and natural history of HCV infection. |
| Q92142929 | Epidemiology of Hepatocellular Carcinoma |
| Q41991379 | Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. |
| Q27025083 | Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? |
| Q38667063 | Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis |
| Q36336005 | Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China |
| Q46772423 | Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis |
| Q40098372 | Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response. |
| Q42277946 | Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection |
| Q38638550 | Evidence for association between hepatitis C virus and Parkinson's disease |
| Q37768335 | Evolving challenges in hepatic fibrosis |
| Q36738517 | Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer? |
| Q48188798 | Exercise might prevent cirrhosis in overweight and obese adults. |
| Q61802124 | Experiences with interferon-free hepatitis C therapies: addressing barriers to adherence and optimizing treatment outcomes |
| Q33576531 | Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection |
| Q37245420 | Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review |
| Q38353529 | Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. |
| Q33571517 | Frontiers in the treatment of hepatitis C virus infection |
| Q36221650 | Fueling fibrosis in chronic hepatitis C. |
| Q37107125 | Functions of autophagy in normal and diseased liver |
| Q41711879 | Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway. |
| Q38237281 | GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection |
| Q46902016 | Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C). |
| Q36373495 | Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C) |
| Q61764128 | Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease |
| Q40079204 | Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. |
| Q37077112 | Global control of hepatitis C: where challenge meets opportunity |
| Q30240220 | Global epidemiology and burden of HCV infection and HCV-related disease |
| Q30245058 | Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes |
| Q31012317 | HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape |
| Q61813946 | HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation |
| Q40078740 | HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals. |
| Q91877786 | HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics |
| Q36399139 | HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. |
| Q38226460 | HIV-hepatitis C virus co-infection in the era of direct-acting antivirals |
| Q91956667 | Have incidence rates of liver cancer peaked in the United States? |
| Q34417139 | Health care costs associated with hepatitis C: a longitudinal cohort study |
| Q42992698 | Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study |
| Q91600263 | Heart Transplantation Outcomes in Patients With Hepatitis C Virus Infection: Potential Impact of Newer Antiviral Treatments After Transplantation |
| Q36720150 | Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. |
| Q44083275 | Hepatic steatosis, fibrosis, and cancer in elderly cadavers. |
| Q45359330 | Hepatitis A virus vaccination in persons with hepatitis C virus infection: consequences of quality measure implementation |
| Q37627088 | Hepatitis B and C in African Americans: current status and continued challenges |
| Q38501726 | Hepatitis C Infection in the Elderly |
| Q59357438 | Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers |
| Q38483255 | Hepatitis C Management and the Infectious Diseases Physician: A Survey of Current and Anticipated Practice Patterns. |
| Q35610571 | Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. |
| Q36858898 | Hepatitis C Virus Testing and Linkage to Care in North Carolina and South Carolina Jails, 2012-2014 |
| Q41931443 | Hepatitis C Virus Testing for Case Identification in Persons Born during 1945-1965: Results from Three Randomized Controlled Trials |
| Q33717116 | Hepatitis C Virus and Liver Transplantation |
| Q37206722 | Hepatitis C among clients of health care for the homeless primary care clinics |
| Q42202758 | Hepatitis C beware--the end is nigh |
| Q26799924 | Hepatitis C cirrhosis: New perspectives for diagnosis and treatment |
| Q41758808 | Hepatitis C in African Americans |
| Q57167190 | Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment |
| Q39576325 | Hepatitis C variability, patterns of resistance, and impact on therapy |
| Q28079580 | Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe |
| Q36871894 | Hepatitis C virus Genotype 1a core gene nucleotide patterns associated with hepatocellular carcinoma risk. |
| Q41572035 | Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study |
| Q37358615 | Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care |
| Q35139900 | Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States |
| Q37390189 | Hepatitis C virus in pregnancy |
| Q35219812 | Hepatitis C virus infection: from margin to center in rhode island and beyond |
| Q45355364 | Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention |
| Q42221769 | Hepatitis C virus testing perspectives among primary care physicians in four large primary care settings |
| Q38620824 | Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. |
| Q36428322 | Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis |
| Q35501190 | Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade |
| Q52661702 | Hepatitis C virus: Morphogenesis, infection and therapy. |
| Q35010720 | Hepatitis C-related arthropathy: Diagnostic and treatment considerations. |
| Q42407045 | Hepatitis C: the end of the beginning and possibly the beginning of the end. |
| Q36199751 | Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice |
| Q29616359 | Hepatocellular carcinoma |
| Q35790424 | Hepatocellular carcinoma in Asia: Prevention strategy and planning |
| Q38046452 | Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. |
| Q35668716 | Hepatocellular carcinoma: From diagnosis to treatment |
| Q37355835 | Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics |
| Q40082158 | High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic |
| Q36702312 | High Rate of Hospital Admissions Among Patients with Cirrhosis Seeking Care in US Emergency Departments |
| Q41480278 | High-risk liver transplant candidates: An ethical proposal on where to draw the line |
| Q37025212 | Highly active anti-hepatitis C therapy: seven lessons from HIV. |
| Q36858883 | Hospital-Based Hepatitis C Screening of Baby Boomers in a Majority Hispanic South Texas Cohort: Successes and Barriers to Implementation |
| Q38554500 | Host genetic variants influencing the clinical course of hepatitis C virus infection |
| Q47566385 | Host genetic variations associated with disease progression in chronic hepatitis C virus infection |
| Q36236839 | How do persistent infections with hepatitis C virus cause liver cancer? |
| Q39315196 | How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries |
| Q42099374 | Human-scale whole-organ bioengineering for liver transplantation: a regenerative medicine approach |
| Q42857506 | IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. |
| Q38985488 | ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. |
| Q39484209 | Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis |
| Q38324277 | Image-guided ablation of primary liver and renal tumours |
| Q26780368 | Imaging panorama in postoperative complications after liver transplantation |
| Q26738293 | Immunobiology of hepatocarcinogenesis: Ways to go or almost there? |
| Q36953735 | Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients |
| Q39238840 | Impact of birth cohort screening for hepatitis C. |
| Q83846277 | Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C |
| Q48470720 | Impact of sustained virologic response on all-cause mortality |
| Q42190310 | Implementation and evaluation of a multicomponent quality improvement intervention to improve efficiency of hepatitis C screening and diagnosis |
| Q91286693 | Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study |
| Q40878925 | Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis |
| Q40047408 | Improving Hepatitis C Identification: Technology Alone Is Not the Answer. |
| Q64960176 | Improving quality of care in patients with cirrhosis. |
| Q90679258 | Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study |
| Q58750606 | Increased Risk of Hepatocellular Carcinoma Associated With Neighborhood Concentrated Disadvantage |
| Q34777639 | Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection |
| Q37052096 | Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection |
| Q42260788 | Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation |
| Q92772696 | Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis |
| Q33819963 | Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States |
| Q37002923 | Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance |
| Q64960668 | Integrating Care for Patients With Chronic Liver Disease and Mental Health and Substance Use Disorders. |
| Q33988140 | Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients |
| Q28087400 | Interferon-free combination therapies for the treatment of hepatitis C: current insights |
| Q41582122 | Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses |
| Q34424151 | Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? |
| Q38445623 | Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. |
| Q34420891 | Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus |
| Q35122424 | Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. |
| Q43199205 | Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C? |
| Q24243600 | Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units |
| Q39394760 | Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. |
| Q34108430 | Laser ablation for small hepatocellular carcinoma. |
| Q55120164 | Lectins as Promising Therapeutics for the Prevention and Treatment of HIV and Other Potential Coinfections. |
| Q31036824 | Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data |
| Q28084106 | Liver Diseases and Long Non-Coding RNAs: New Insight and Perspective |
| Q42507189 | Liver fibrosis in elderly cadavers: localization of collagen types I, III, and IV, α-smooth muscle actin, and elastic fibers |
| Q40101753 | Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland--using spontaneous resolvers as the benchmark comparator |
| Q37766546 | Loco-regional treatment of hepatocellular carcinoma |
| Q86553049 | Long-term outcomes comparing surgery to embolization-ablation for treatment of solitary HCC<7 cm |
| Q34387277 | MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles |
| Q38584289 | Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances |
| Q34298333 | Management of recurrent hepatitis C following liver transplantation |
| Q26830190 | Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus |
| Q33853664 | Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. |
| Q59351180 | Medical intensive care unit admission among patients with and without HIV, hepatitis C virus, and alcohol-related diagnoses in the United States: a national, retrospective cohort study, 1997-2014 |
| Q43179239 | Medium-sized HCC: achieving effective local tumor control with combined chemoebolization and radiofrequency ablation |
| Q30456389 | MicroRNA signature at the time of clinical HCV recurrence associates with aggressive fibrosis progression post-liver transplantation |
| Q38662504 | Model-free scoring system for risk prediction with application to hepatocellular carcinoma study |
| Q99213143 | Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage |
| Q45731609 | Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. |
| Q21284820 | Molecular functions of thyroid hormones and their clinical significance in liver-related diseases |
| Q30455825 | Molecular profiles of HCV cirrhotic tissues derived in a panel of markers with clinical utility for hepatocellular carcinoma surveillance |
| Q61958643 | Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data |
| Q58552847 | Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct-Acting Antivirals for Hepatitis C |
| Q24635267 | Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma |
| Q37402588 | NBN Gene Polymorphisms and Cancer Susceptibility: A Systemic Review. |
| Q50934392 | Natural History of Hepatitis C. |
| Q42208880 | Natural history and management of hepatitis C: does sex play a role? |
| Q28070168 | New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article |
| Q33560181 | New Therapies for Hepatitis C Virus Infection |
| Q36127059 | New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison |
| Q42024851 | New and Evolving Management Paradigms for Hepatitis C after Liver Transplantation. |
| Q40747582 | New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial). |
| Q40701509 | No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening |
| Q30423320 | Non-invasive diagnosis of advanced fibrosis and cirrhosis |
| Q89558079 | Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965 |
| Q37862375 | Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus |
| Q38201712 | Novel drugs in the management of difficult-to-treat hepatitis C genotypes |
| Q34017968 | Nrf2 pathway activation contributes to anti-fibrosis effects of ginsenoside Rg1 in a rat model of alcohol- and CCl4-induced hepatic fibrosis |
| Q42183623 | Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained? |
| Q38235178 | Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. |
| Q36333842 | Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection |
| Q38251471 | Outcomes after liver transplantation for combined alcohol and hepatitis C virus infection |
| Q41108422 | Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study |
| Q36301391 | Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis |
| Q36848975 | PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis |
| Q33924602 | Patient acceptance of universal screening for hepatitis C virus infection |
| Q38876302 | Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment |
| Q35138230 | Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients |
| Q37021514 | Patients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection |
| Q57152417 | Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid Patients |
| Q37305565 | Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease |
| Q42545888 | Pay now or pay (more) later: tracking the costs of hepatitis C infection |
| Q33400529 | Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy |
| Q37641048 | Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial |
| Q45348539 | Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force |
| Q39204755 | Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy |
| Q54269145 | Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort. |
| Q38755645 | Predictors of hepatitis C testing intention among African American Baby Boomers. |
| Q38176941 | Predictors of hepatitis C treatment response: what's new? |
| Q41366464 | Presence of HCV RNA in peripheral blood mononuclear cells may predict patients response to interferon and ribavirin therapy |
| Q49911983 | Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection |
| Q36067623 | Prevalence and knowledge of hepatitis C in a middle-aged population, Dunedin, New Zealand |
| Q38323723 | Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs |
| Q40690948 | Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study |
| Q28272678 | Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges |
| Q38212793 | Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus |
| Q51852531 | Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008. |
| Q36788468 | Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis |
| Q36456976 | Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma |
| Q53123382 | Proposal of a predictive model for advanced fibrosis containing Wisteria floribunda agglutinin-positive Mac-2-binding protein in chronic hepatitis C. |
| Q38014646 | Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care |
| Q30251763 | Protecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice |
| Q38264060 | Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy |
| Q42269612 | Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial |
| Q40706124 | Quality of Care Provided by Hepatologists to Patients with Cirrhosis at Three Parallel Health Systems |
| Q38068356 | Quality of life in cirrhosis |
| Q39140437 | Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III. |
| Q35800747 | Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C |
| Q36100521 | Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study |
| Q33430833 | Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis |
| Q40227140 | Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study. |
| Q26752433 | Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease |
| Q28076883 | Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline |
| Q47298278 | Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis |
| Q51831518 | Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program. |
| Q40409092 | Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. |
| Q30241881 | Reinventing HCV Treatment: Past and Future Perspectives |
| Q38260704 | Relative effects of heavy alcohol use and hepatitis C in decompensated chronic liver disease in a hospital inpatient population |
| Q42219509 | Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters |
| Q36716620 | Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience |
| Q36858838 | Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012-2014. |
| Q40317993 | Retention in buprenorphine treatment is associated with improved HCV care outcomes |
| Q38380343 | Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication. |
| Q42213984 | Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. |
| Q40039560 | Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics |
| Q57215000 | Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea |
| Q41482932 | Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis |
| Q33692635 | Role of Sleep Disturbance in Chronic Hepatitis C Infection |
| Q37399645 | Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment |
| Q40058097 | Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis |
| Q39099624 | Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. |
| Q40171094 | Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older |
| Q35926098 | Screening for hepatitis C in average and high-risk populations of Qatar using rapid point-of-care testing |
| Q33774344 | Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. |
| Q44684380 | Seropositive abdominal and thoracic donor organs are largely underutilized |
| Q29417108 | Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy |
| Q47560335 | Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV. |
| Q38945878 | Sex difference in liver-related mortality and transplantation associated with dietary cholesterol in chronic hepatitis C virus infection |
| Q45326298 | Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment |
| Q35491398 | Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? |
| Q40035445 | Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience |
| Q38985491 | Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis. |
| Q38219424 | Sofosbuvir (Sovaldi) for the treatment of hepatitis C. |
| Q39289372 | Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience. |
| Q58579826 | Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection |
| Q30235430 | Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure |
| Q38248974 | Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease |
| Q39067369 | Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment |
| Q26740233 | Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C |
| Q42226125 | Strategies to manage hepatitis C virus (HCV) disease burden. |
| Q55424407 | Survey of US Correctional Institutions for Routine HCV Testing. |
| Q34522481 | Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis |
| Q26858962 | Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C |
| Q37996076 | Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. |
| Q38702025 | The Burden of Rehospitalization for Patients With Liver Cirrhosis |
| Q41930407 | The Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor |
| Q59356988 | The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial |
| Q38010582 | The application and mechanism of action of ribavirin in therapy of hepatitis C. |
| Q40168920 | The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics |
| Q35168083 | The changing burden of hepatitis C virus infection in the United States: model-based predictions. |
| Q26795559 | The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment |
| Q42242240 | The contribution of viral hepatitis to the burden of chronic liver disease in the United States |
| Q39137372 | The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. |
| Q35691411 | The current economic burden of cirrhosis. |
| Q64061966 | The distribution and socioeconomic burden of Hepatitis C virus in South Australia: a cross-sectional study 2010-2016 |
| Q34512967 | The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective |
| Q39707313 | The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam |
| Q92690149 | The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk |
| Q38181631 | The impact of hepatitis C burden: an evidence-based approach. |
| Q37098107 | The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean. |
| Q36185899 | The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan |
| Q37463091 | The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care plan |
| Q30250096 | The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma |
| Q30412494 | The interaction of metabolic factors with HCV infection: does it matter? |
| Q42873883 | The next step for taribavirin |
| Q42263146 | The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection |
| Q45343893 | The ongoing debate of who to treat for chronic hepatitis C virus |
| Q39213684 | The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm |
| Q39064153 | The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. |
| Q45358076 | The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection |
| Q47121548 | The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C. |
| Q38723427 | Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. |
| Q36933104 | Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues. |
| Q45323547 | Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents |
| Q54548523 | Total joint arthroplasty in patients with chronic infectious liver disease. |
| Q34484872 | Toward a more accurate estimate of the prevalence of hepatitis C in the United States |
| Q46207504 | Toward the Effective Co-management of Patients with Cirrhosis by Primary Care Providers and Specialists |
| Q91656059 | Training the next generation of hepatologist: What will they need to know? |
| Q42379112 | Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma |
| Q37947148 | Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations |
| Q39049983 | Transplant-related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma |
| Q38790455 | Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy |
| Q38243001 | Treating hepatitis C in the elderly: the future is near? |
| Q35992555 | Treating hepatitis C infection by targeting the host |
| Q36076049 | Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis |
| Q54268463 | Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV. |
| Q38177972 | Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles |
| Q40973051 | Treatment of hepatitis C in patients with HIV. |
| Q38460386 | Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy |
| Q41934079 | Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. |
| Q42173527 | Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials |
| Q42591044 | Trends in Liver Transplantation in Hepatitis C Virus-Infected Persons, United States |
| Q33400231 | Trends in the prevalence of thrombocytopenia among individuals infected with hepatitis C virus in the United States, 1999-2008 |
| Q37980539 | UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients |
| Q30564165 | Underestimation of liver-related mortality in the United States. |
| Q38685582 | Universal screening for chronic hepatitis C virus |
| Q40219302 | Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. |
| Q45330154 | Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office |
| Q61446100 | Update on the management of gastrointestinal varices |
| Q35233962 | Urinary biomarkers of catechins and risk of hepatocellular carcinoma in the Shanghai Cohort Study |
| Q47546983 | Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates |
| Q39229834 | Use of telehealth to treat and manage chronic viral hepatitis in regional Queensland. |
| Q37322087 | Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States |
| Q40374302 | Variation in Treatment Priorities for Chronic Hepatitis C: A Latent Class Analysis |
| Q36333772 | Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection |
| Q40837524 | Viral hepatitis: HCV compartmentalization in HCC: driver, passenger or both? |
| Q51056377 | Viral hepatitis: Scaling up HCV treatment in resource-limited countries. |
| Q35928048 | Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir |
| Q36812745 | Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer |
| Q41123248 | Visual detection of serum asialohaptoglobin by plasmonic sandwich ELLSA--a new platform for cirrhosis diagnosis |
| Q34290930 | Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic hepatitis C |
| Q45958552 | What defines high quality care for patients with chronic hepatitis C and why should we care? |
| Q38569681 | What does the pharmacological future of treating chronic hepatitis C look like? |
| Q38685566 | Why I do not treat patients for mild disease |
| Q34781537 | Will there be a vaccine to prevent HCV infection? |
| Q38806381 | Workforce in hepatology: Update and a critical need for more information |
Search more.